RT Journal Article
SR Electronic
T1 Loss of BRCA2 Correlates with Reduced Long-term Survival of Sporadic Breast Cancer Patients
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 281
OP 290
VO 24
IS 1
A1 HAMPL, J.A.
A1 HAMPL, M.
A1 REIß, G.
A1 KOCH, R.
A1 SAEGER, H.-D.
A1 SCHACKERT, H.K.
YR 2004
UL http://ar.iiarjournals.org/content/24/1/281.abstract
AB Background: The present study was undertaken to analyze the prognostic value of loss of heterozygosity (LOH) at 13q12-13, 17q21 and 17p13, harboring BRCA2, BRCA1 and p53 to predict the clinical course of sporadic breast cancer patients. Materials and Methods: LOH analysis was performed by PCR amplification of genomic DNA using nine microsatellite markers. Fifty-three sporadic breast cancer patients were followed clinically for a median of 55 months. Disease-free and overall survival was documented as the endpoint for statistical evaluation. Results: Patients presenting with LOH in their tumor samples at at least one of the loci examined were found to have a reduced overall survival time compared to those retaining heterozygosity (61% versus 48%). Focusing on the three target regions, patients with LOH at the BRCA2 locus died earlier compared to patients retaining heterozygosity (69% versus 50%) and, in addition, BRCA2 LOH-positive patients showed a shorter metastasis-free interval (30 versus 37 months). In a multivariate analysis, LOH at the 13q12-13 locus was found to be a significant predictor for reduced long-term survival (risk ratio 2.33, 95% C.I., 1.0-5.3; p<0.05) and earlier metastases manifestation (risk ratio 2.32, 95% C.I., 1.0-5.3, p<0.05). Conclusion: Allelic loss at the BRCA2 locus may be of use as a negative predictor for metastases-free and overall survival.